ALXN Alexion Pharmaceuticals, Inc.

109.531.00 (+0.92%)
Close: November 21, 2019

Quote

Previous Close
$109.53
Day Range
$108.00-$110.07
52 Week Range
$92.56-$141.86
Volume
1,640,754
Avg Volume
1,725,491
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$24.24B
Enterprise Value (EV)
$25.66B
PE Ratio
16.67
EV/EBITDA
12.71
Price/Sales
5.81
Price/Book
2.64
PEG Ratio
0.44

Financials

Revenue
$4.13B
Gross Profit
$3.44B
EBITDA
$2.02B
EPS, ttm
$6.57
Profit Margin
1.88%
Revenue/Employee
$1.56M
Next Earnings Date
2/3/2020 (73 days)
Debt to Equity
35%
Debt
$2.99B
Cash
$1.56B
Net Debt
$1.42B

Performance

Beta
1.32
200 Day Moving Avg
$119.49
50 Day Moving Avg
$103.80
52 Week Change
-8.11%
YTD Change
11.61%
1 Month Change
7.74%
3 Month Change
-5.49%
6 Month Change
-15.74%
1 Year Change
-8.11%
2 Year Change
0.04%
5 Year Change
-43.64%

Share Count

Shares Outstanding
221.3M
Float
220.4M
Restricted Shares
922.3K
Restricted Shares, %
0.42%

Alexion Pharmaceuticals, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Ludwig N. Hantson

Website: http://www.alexion.com

Description: Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma. The company was founded by Joseph A. Madri, David W. Keiser, Stephen P. Squinto and Leonard Bell in January 1992 and is headquartered in Boston, MA.

Employees: 2,656